Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01568866 · OUTCOME

Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients · Source last updated 2022-11-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
mmHg
Interval / dispersion
Standard Deviation
Time frame
Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).

What was measured

Pulmonary artery pressure was measured using transthoracic echocardiogram.

Analysis population: Cardiopulmonary Safety Evaluable subgroup with available PASP data at baseline; "n" indicates participants whose results were available at both the baseline and the specified post-baseline visit.

Groups in this outcome

Bortezomib + DEX

Participants received bortezomib 1.3 mg/m² administered intravenously (IV) or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone (DEX) 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.

Carfilzomib + DEX

Participants received 20 mg/m² carfilzomib administered by IV infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib + DEX52
Carfilzomib + DEX45

Reported measurements

Week 12 (n=34, 30)
Values in mmHg · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bortezomib + DEX0.311.72Not reportedNot reportedNot reported
Carfilzomib + DEX2.811.44Not reportedNot reportedNot reported
Week 24 (n=22, 20)
Values in mmHg · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bortezomib + DEX1.78.47Not reportedNot reportedNot reported
Carfilzomib + DEX3.413.63Not reportedNot reportedNot reported
Week 36 (n=12, 14)
Values in mmHg · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bortezomib + DEX4.07.24Not reportedNot reportedNot reported
Carfilzomib + DEX2.613.55Not reportedNot reportedNot reported
End of Treatment (n=21, 14)
Values in mmHg · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bortezomib + DEX3.48.14Not reportedNot reportedNot reported
Carfilzomib + DEX0.911.40Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        11.72
        value
        0.3
      2. group Id
        OG001
        spread
        11.44
        value
        2.8
    title
    Week 12 (n=34, 30)
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        8.47
        value
        1.7
      2. group Id
        OG001
        spread
        13.63
        value
        3.4
    title
    Week 24 (n=22, 20)
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        7.24
        value
        4.0
      2. group Id
        OG001
        spread
        13.55
        value
        2.6
    title
    Week 36 (n=12, 14)
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        8.14
        value
        3.4
      2. group Id
        OG001
        spread
        11.40
        value
        0.9
    title
    End of Treatment (n=21, 14)
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    2. group Id
      OG001
      value
      45
    units
    Participants
description
Pulmonary artery pressure was measured using transthoracic echocardiogram.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received bortezomib 1.3 mg/m² administered intravenously (IV) or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone (DEX) 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
    id
    OG000
    title
    Bortezomib + DEX
  2. description
    Participants received 20 mg/m² carfilzomib administered by IV infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
    id
    OG001
    title
    Carfilzomib + DEX
param Type
MEAN
population Description
Cardiopulmonary Safety Evaluable subgroup with available PASP data at baseline; "n" indicates participants whose results were available at both the baseline and the specified post-baseline visit.
reporting Status
POSTED
time Frame
Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).
title
Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)
type
SECONDARY
unit Of Measure
mmHg

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice